BioImagene launches new Ki-67 algorithm for prostate image analysis

9 April 2009

BioImagene has launched a new Ki-67 prostate image analysis algorithm. The algorithm, which is part of Virtuoso, its suite of web-based software applications for digital pathology, is used to detect and provide quantitative measurement of the protein biomarker Ki-67.

Research has shown that Ki-67 immunohistochemistry may be a valuable predictor of biochemical relapse and distant metastasis after prostatectomy and radiation therapy.

“The launch of the Ki-67 algorithm that can be used in a research setting illustrates the potential impact digital pathology can have on the practice of medicine,” commented Dr Ajit Singh, CEO BioImagene. “In the coming months, we expect to launch a series of additional algorithms to serve the pathology and research communities.”

The launch of the Ki-67 algorithm adds to the company’s growing offering of image-analysis tools. BioImagene also has a PIN4 algorithm for prostate cancer research, and FDA-cleared algorithms to assess HER2/neu immunohistochemistry status. The iScan Coreo and associated software are used to detect and provide a quantitative measurement of HER2/neu, a protein measured in breast cancer patients to determine their candidacy for treatment with the Genentech drug Herceptin.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. BioImagene launches new Ki-67 algorithm for prostate image analysis 9 April 2009 BioImagene has launched a new Ki-67 prostate image analysis algorithm. The algorithm, which is part of Virtuoso, its suite of web-based software applications for digital pathology, is used to detect and provide quantitative measurement of the protein biomarker Ki-67. Research has shown that Ki-67 immunohistochemistry may be a valuable predictor of biochemical relapse and distant metastasis after prostatectomy and radiation therapy. “The launch of the Ki-67 algorithm that can be used in a research setting illustrates the potential impact digital pathology can have on the practice of medicine,” commented Dr Ajit Singh, CEO BioImagene. “In the coming months, we expect to launch a series of additional algorithms to serve the pathology and research communities.” The launch of the Ki-67 algorithm adds to the company’s growing offering of image-analysis tools. BioImagene also has a PIN4 algorithm for prostate cancer research, and FDA-cleared algorithms to assess HER2/neu immunohistochemistry status. The iScan Coreo and associated software are used to detect and provide a quantitative measurement of HER2/neu, a protein measured in breast cancer patients to determine their candidacy for treatment with the Genentech drug Herceptin. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.